Trial code Clinical progression Overall survival
  Progression rate (%) HR (p-value) Mortality rate (%) HR (p –value)
MRC trial M0 subgroup EORTC 30846 38 vs. 59   Not reported   Not reported (p<0,001) Not reported 59 vs. 70 61 vs. 62 Not reported (p=0,02) 1,23 (NS)
EPC (1) 44 vs. 61 0,53 (p<0,0001) 34 vs. 41 0,81(p=0,097)
EPC (2) 29 vs. 32 0,81 (p=0,018) 25 vs. 21 1,23 (p=0,050)
SAK 08/88 Not reported Not reported 24 vs. 37 0,99(p=0,096)
EORTC 30891 Not reported Not reported 52.2% vs. 57 1,25 (p=0,434)
HR, Hazard ratio
Table 2: Efficacy outcomes.